Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
RNA trans-splicing gene therapies for aggressive cancers
Spliceor is a University of Cambridge spinout developing RNA trans-splicing gene therapies for aggressive cancers. Its platform is designed to produce therapeutic messenger RNA selectively in targeted cells by joining segments from different RNA molecules. Machine learning helps refine the constructs and optimise…
Immune cell separation and expansion platform for cell therapies
CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation, and expansion in a single workflow. The system exploits the natural migratory behaviour of immune cells across membranes, replacing…
Small molecule GPR65 inhibitors restoring immune response in solid tumours
Pathios Therapeutics is a clinical-stage drug discovery company developing small molecule inhibitors of GPR65, a pH-sensing G protein-coupled receptor that drives immunosuppressive polarisation of tumour-associated macrophages in the acidic tumour microenvironment. By blocking GPR65, Pathios aims to restore…
AI-driven rescue and development of failed drug candidates
Ignota Labs is a biotechnology company that identifies, in-licenses and redevelops drug candidates that have failed clinical development due to toxicity. Using deep learning applied to cheminformatics and bioinformatics data, the company resolves the mechanistic basis of safety failures and makes targeted chemical…
Non-CRISPR RNA-guided gene editing and modulation platform
Pencil Biosciences is a gene editing company developing a fully synthetic, RNA-guided genome modulation platform as an alternative to CRISPR-based technologies. The system is modular in design, significantly smaller than Cas-based tools, and intended to enable precise gene knock-ins without DNA cleavage. Primary…
Non-viral gene therapy platform enabling durable nuclear DNA delivery
Gramics Bio develops a gene therapy platform solving a key limitation of lipid nanoparticle delivery: enabling therapeutic DNA to reach the cell nucleus for durable expression without viral vectors. By programming specificity into synthetic DNA sequences rather than new delivery chemistries, the technology combines…
AI-designed combination therapies for cancer
Big Picture Bio is a preclinical biotechnology company designing combination therapies for cancer. Its generative model simulates how tumours, immune cells and surrounding tissue interact, and is used to predict which drug combinations, and which sequences of treatment, are most likely to suppress resistant cancer…
Thermostable vaccine platform eliminating cold chain dependency
Stablepharma is a clinical-stage biotechnology company developing fridge-free vaccines and biologicals using. Its technology reformulates temperature-sensitive products into thermostable formulations that remain potent without refrigeration. The technology addresses cold chain failure, which the WHO estimates causes…
Oxygen-generating nanoparticles to overcome hypoxia in solid tumours
StimOxyGen is a preclinical-stage biotechnology company developing pH-responsive nanoparticle formulations to address tumour hypoxia, a major barrier to effective cancer treatment. The technology uses a biodegradable polymer coating that dissolves in the acidic tumour microenvironment, transiently generating localised…
RNA-based gene control systems for safer cell and gene therapies
Concinnity Genetics is a biotechnology company developing RNA-based control systems that enable precise regulation of gene therapies after administration. Its technology allows therapeutic gene expression to be modulated or reduced in response to side effects or clinical need, addressing a fundamental safety…
Mitochondrial disease drug discovery subsidiary of Astellas Pharma
Astellas Engineered Small Molecules U.K. is a Cambridge-based drug discovery subsidiary of Astellas Pharma, operating as part of the company's Mitobridge Division alongside its US counterpart Mitobridge Inc. Originally founded as Nanna Therapeutics and acquired by Astellas in 2020, the entity applies a proprietary…
Synthetic platform for precision delivery of biologics in tissue repair
Renovos Biologics is a biotech company developing precision delivery technologies for regenerative medicine, drawing on decades of academic research in skeletal stem cells, biomaterials and translational orthopaedic science at the University of Southampton. Its proprietary synthetic platform enables injectable,…
Novel methylation amplification platform for clinical genomic diagnostics
Syndex Bio is a Cambridge-based biotechnology company developing a proprietary platform technology that enables amplification of DNA methylation for the first time. Unlike conventional PCR, which cannot preserve 5-methylcytosine signals, mcPCR copies both the four-base DNA code and its methylation patterns from…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…
Private umbilical cord blood and tissue stem cell banking service
Future Health Biobank is the UK's largest private stem cell bank, providing collection, processing, and long-term cryogenic storage of umbilical cord blood and cord tissue for families. Operating from an HTA- and MHRA-licensed laboratory in Nottingham, the company performs in-house PCR, serology, and flow cytometry…
ADC pipeline targeting mutant stem cells in blood cancers
Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers. Its pipeline targets the mutant stem and progenitor cells that drive disease progression and fibrosis, with the aim of modifying rather than…
Quantum-informed computational design of covalent drug candidates
Axiom Therapeutics is a London biotechnology company using molecular physics and machine learning to design covalent small-molecule medicines. Its computational drug-discovery platform models interactions between reactive compounds and biological targets, helping design selective inhibitors for difficult-to-drug…
Amniotic membrane biotherapies for ocular surface repair and regeneration
NuVision Biotherapies is a regenerative medicine company developing tissue-based biotherapies for ocular surface disease and trauma. Its proprietary processing technology manufactures dry-preserved human amniotic membrane grafts that retain the membrane's natural barrier and healing properties whilst enabling ambient…
Targeted antibody therapeutics for cancer and autoimmune disease
Medannex is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics targeting annexin-A1, a protein implicated in cancer progression, autoimmunity, and inflammation. Its lead asset, MDX-124, is the first therapeutic antibody to target annexin-A1 and is currently being evaluated in the…
Bacillus spore-based vaccines, drug delivery and probiotic therapeutics developer
SporeGen is a biotechnology company working exclusively on spore-forming Bacillus bacteria to develop vaccines, drug delivery platforms and probiotic therapeutics. The company's SporeVax platform uses bacterial spores as a vaccine delivery agent, and its SPOR-COV nasal spray, developed with a commercial partner, aims…